[go: up one dir, main page]

AR133966A1 - UNA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR EL CÁNCER QUE INCLUYE UN CONSTRUCTO DE ÁCIDO NUCLEICO QUE CODIFICA LA PROTEÍNA p53 - Google Patents

UNA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR EL CÁNCER QUE INCLUYE UN CONSTRUCTO DE ÁCIDO NUCLEICO QUE CODIFICA LA PROTEÍNA p53

Info

Publication number
AR133966A1
AR133966A1 ARP240102617A ARP240102617A AR133966A1 AR 133966 A1 AR133966 A1 AR 133966A1 AR P240102617 A ARP240102617 A AR P240102617A AR P240102617 A ARP240102617 A AR P240102617A AR 133966 A1 AR133966 A1 AR 133966A1
Authority
AR
Argentina
Prior art keywords
utr
mrna
protein
preventing
treating cancer
Prior art date
Application number
ARP240102617A
Other languages
English (en)
Inventor
Inn Ah Kim
Joo Yun Byun
Seung Hyun Shin
Ji Hee Lee
Chang Gyu Lim
Young Jin Han
Yong Ho Heo
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AR133966A1 publication Critical patent/AR133966A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan un ARN mensajero (ARNm) que incluye una región no traducida 5’ (5’UTR), una secuencia que codifica una proteína p53 y una región no traducida 3’ (3’UTR), una composición para suministrar el ARNm o p53 a un sujeto, que comprende el ARNm, y una composición y un método para prevenir o tratar el cáncer. Reivindicación 1: Un ARNm que comprende una región no traducida 5’ (5’UTR) no natural, una secuencia que codifica un polipéptido y una región no traducida 3’ (3’UTR) no natural, en donde la 5’UTR no forma una estructura secundaria, la secuencia que codifica un polipéptido es una secuencia que codifica p53 o un fragmento funcional de esta, y la 3’UTR tiene: una estructura secundaria representada por la siguiente notación de puntos-paréntesis: .(((((...........(((...(((((.(((....))).)))))...)))..(((((((..((((....((((((.(((((.......)))))..))).)))))))...))))))).......(((....)))............(((.........(((....))))))..)))); o una estructura secundaria representada por la siguiente notación de puntos-paréntesis: ((((((((((((...(((((.((........((((((((.........))))))))))))))).....(((...))).....))))))))))))..((((((((((((....))))))...)))))).....((((((...))))))........... en donde, en la notación de puntos-paréntesis, un punto denota bases desapareadas en una secuencia, y “(” y “)” denota bases apareadas en una secuencia. Reivindicación 9: Una composición que comprende, como un principio activo, el ARNm de una cualquiera de las reivindicaciones 1 a 7 o ADN que codifica el ARNm.
ARP240102617A 2023-09-27 2024-09-27 UNA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR EL CÁNCER QUE INCLUYE UN CONSTRUCTO DE ÁCIDO NUCLEICO QUE CODIFICA LA PROTEÍNA p53 AR133966A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230130728 2023-09-27
KR20240043273 2024-03-29

Publications (1)

Publication Number Publication Date
AR133966A1 true AR133966A1 (es) 2025-11-19

Family

ID=95201937

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102617A AR133966A1 (es) 2023-09-27 2024-09-27 UNA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR EL CÁNCER QUE INCLUYE UN CONSTRUCTO DE ÁCIDO NUCLEICO QUE CODIFICA LA PROTEÍNA p53

Country Status (4)

Country Link
KR (1) KR20250047641A (es)
AR (1) AR133966A1 (es)
TW (1) TW202530405A (es)
WO (1) WO2025071343A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2205618T3 (en) * 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
BR112018069823A2 (pt) * 2016-03-31 2019-04-09 Ethris Gmbh molécula de dna, vetor, célula hospedeira, composição, molécula de rna, molécula de ácido nucleico, composição farmacêutica, kit, e, uso de uma utr
MX2023015487A (es) * 2021-06-24 2024-04-10 Hanmi Pharmaceutical Co Ltd Región 5' no traducida no natural y región 3' no traducida y uso de estas.
KR20230083893A (ko) * 2021-12-03 2023-06-12 고려대학교 산학협력단 번역 효율이 향상된 5'-utr, 이를 포함하는 합성 핵산 분자 및 이를 포함하는 백신 또는 치료제 조성물
CN118434871A (zh) * 2021-12-22 2024-08-02 韩美药品株式会社 冠状病毒疫苗

Also Published As

Publication number Publication date
WO2025071343A1 (ko) 2025-04-03
KR20250047641A (ko) 2025-04-04
TW202530405A (zh) 2025-08-01

Similar Documents

Publication Publication Date Title
WO2020198509A3 (en) Modified oligonucleotides with increased stability
PE20230179A1 (es) Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
BR112022012921A2 (pt) Métodos para editar de forma alvejada ácido ribonucleico e para tratar a síndrome de usher tipo ii, ácido ribonucleico de recrutamento da adenosina desaminase, construto ou vetor de entrega, célula, e, uso do ácido ribonucleico de recrutamento da adenosina desaminase ou do construto ou vetor de entrega
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
US9861574B2 (en) 2-fluoro-modified RNAs as immunostimulators
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
CL2020002704A1 (es) Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial
CL2021002585A1 (es) Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central
PE20241933A1 (es) Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt)
MX394033B (es) Un Método para Inhibir o Reducir una Infección Viral por Coronavirus
DK1409506T3 (da) Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
AR090641A1 (es) Composiciones y metodos para inhibir la expresion del gen alas1
WO2006031901A3 (en) SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
MX2025008039A (es) Uso de oligonucleótidos antisentido multisegmentados modificados
MX2021007241A (es) Acido ribonucleico (arn) que codifica para una proteina.
MX2023003039A (es) Agentes y metodos para el suministro dirigido a celulas.
MX2020012652A (es) Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
RU2014125496A (ru) Комбинированная терапия для лечения нарушений слуха и равновесия
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
MX2023012833A (es) Opciones terapéuticas y composiciones de arn mensajero.
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
PE20241479A1 (es) Agentes de interferencia de arn de mapt